Description: Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3 encoding Trk A, Trk B, and Trk C proteins, respectively. The latters are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. In various cancers, oncogenic fusions involving the kinase domain of NTRK1, 2, or 3 are present. Pan-Trk IHC is a time- and tissue-efficient screen for NTRK fusions, particularly in driver-negative advanced malignancies and potential cases of secretory carcinoma and congenital fibrosarcoma. Pan-Trk IHC can help determine whether translation occurs for novel NTRK rearrangements.